Cystic Fibrosis Drugs Market Size 2034 | Verona Pharmaceuticals, Laurent Pharmaceuticals Inc., Vertex Pharmaceuticals, SpliSense Ltd., Krystal Biotech, Inc., Aridis Pharmaceuticals, Inc., 4D Molecular Therapeutics

DelveInsight's report titled "Cystic Fibrosis Therapeutics Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of burns, historical and forecasted epidemiology, as well as the burns market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The report examines current treatment market methodologies and algorithms for cystic fibrosis, assessing the overall market potential, identifying business prospects, and addressing pertinent unmet medical requirements.

Discover which therapies are expected to grab the Cystic Fibrosis market share @ Cystic Fibrosis Market Outlook- https://www.delveinsight.com/sample-request/cystic-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Cystic Fibrosis Market Research Report
• As per DeveInsight analysis, in 2023, the estimated total diagnosed prevalent cases of cystic fibrosis in the 7MM were approximately 67,897 cases in 2023. This expanded genetic testing will facilitate the identification of more individuals with cystic fibrosis, contributing to the overall increase in reported cases.
• In 2023, among the 7MM, the US accounted for the highest diagnosed prevalent cases of cystic fibrosis with approximately 33,391 cases. These cases are expected to increase during the forecast period (2024-2034).
• Among the EU4 and the UK, the UK had the highest diagnosed prevalent cases of cystic fibrosis with nearly 11,275 cases, followed by France, and Germany with approximately 7,506, and 7,043 diagnosed prevalent cases respectively.
• The increase in Cystic Fibrosis Market Size is a direct consequence of expected launch of potential therapies, along with increasing awareness and development of novel therapies.
• As per DelveInsight's analysis, a higher percentage of diagnosed prevalent cases were males, except Japan, where females occupy a larger patient pool than males.
• The leading Cystic Fibrosis Companies working in the market include Chiesi Farmaceutici S.p.A., Medidata Solutions, Bayer, Verona Pharmaceuticals, Eloxx Pharmaceuticals, Inc., Vertex Pharmaceuticals, Santhera Pharmaceuticals, Laurent Pharmaceuticals Inc., and others.
• Promising Cystic Fibrosis Pipeline Therapies in the various stages of development include Ciprofloxacin (Cipro Inhale), BAYQ3939, P-1037, Hypertonic Saline, VX-371 + HS, inhaled mannitol, and others.

Cystic Fibrosis Overview
Cystic fibrosis (CF) is an autosomal recessive condition known as brought on by mutations in the CF transmembrane conductance regulator (CFTR) gene. F508del is the most prevalent variation reported globally, but there are over 2000 others, although not all of these are disease-causing. CF is usually diagnosed in childhood, however adults with no symptoms (or mild symptoms) during their youth can still be found to have the disease. The signs and symptoms of CF generally begin to occur around 6-8 months after birth, though this can differ significantly from person to person. Symptoms tend to differ depending on age and can affect various areas of the body.

Cystic Fibrosis Epidemiology Segmentation in the 7MM
• Cystic Fibrosis Diagnosed Prevalent Cases
• Cystic Fibrosis Age-specific Diagnosed Prevalent Cases
• Cystic Fibrosis Gender-specific Diagnosed Prevalent Cases
• Cystic Fibrosis Mutation-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Cystic Fibrosis epidemiology trends @ Cystic Fibrosis Epidemiological Insights- https://www.delveinsight.com/sample-request/cystic-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Cystic Fibrosis Drugs Market
The current drugs for CF focus on symptomatic improvement, complication prevention as well as more recently, protein rectifiers to correct underlying structural and functional abnormalities. The paradigm includes inhaled antibiotics for treatment of chronic lung infection, mucolytic for reducing the viscosity of pulmonary mucus, pancreatic enzyme replacement therapy (PERT) for the treatment of CF-associated exocrine pancreatic insufficiency(PPI), and CFTR modulators for enhancing CFTR function, targeting the underlying cause of the disease.

Cystic Fibrosis Market Insights
In condition such as Cystic Fibrosis (CF), close collaboration among all stakeholders is important because collaborative studies and systematic data collection will help further development in the disease management. As a next step, a global prospective study will help all the research fraternity in better understanding of biomarkers and diagnostic tests which will be relevant for future therapeutic clinical trials. In the present scenario a number of agents are being investigated. These molecules are in early, middle and late Phase of their clinical investigation.

Cystic Fibrosis Companies and Therapies
 Vertex Pharmaceuticals: VX-659
 Proteostasis Therapeutics Inc.: PTI-808
 Galapagos NV: GLPG2222 50 mg
 InterMune: Interferon Gamma-1b
 Verona Pharma PLC: RPL554
 PTC Therapeutics: Ataluren

Cystic Fibrosis Drugs Uptake
ELX-02 (NB-124) is a synthetic aminoglycoside that acts as a ribosome protein modulator. It is a eukaryotic ribosomal selective glycoside (ERSG) that has designed to increase the read-through activity in patients with nonsense mutations which enables the production of sufficient amounts of full-length functional protein to restore activity. The US FDA granted FTD for ELX-02, Eloxx Pharmaceuticals, Inc., drug candidate intended to treat cystic fibrosis patients with nonsense mutations. In addition, the FDA and European Commission granted ELX-02, ODD for the Cystic Fibrosis treatment.

Lonodelestat (previously known as POL6014), is a highly potent and selective peptide inhibitor of human neutrophil elastase (hNE), in development for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases such as non-cystic fibrosis bronchiectasis (NCFB), alpha1 antitrypsin deficiency (AATD) and primary ciliary dyskinesia (PCD). Lonodelestat has ODD for the treatment of CF as well as for AATD and PCD in both EU and US.
LAU-7b (fenretinide) is a novel oral form of fenretinide, an atypical retinoid that acts on certain cell membrane lipids involved in both viral replication and immune-inflammatory responses. Results from a Phase Ib clinical trial in adult patients with CF have shown LAU-7b to have good safety and pharmacokinetic profiles, coupled with promising pharmacodynamics on specific markers of inflammation. Currently, Laurent Pharma has completed two Phase II clinical studies with LAU-7b, a first-in-class pro-resolving drug candidate, in cystic fibrosis and COVID-19.

Scope of the Cystic Fibrosis Market Research Report
• Coverage- 7MM
• Cystic Fibrosis Companies- Chiesi Farmaceutici S.p.A., Medidata Solutions, Bayer, Verona Pharmaceuticals, Eloxx Pharmaceuticals, Inc., Vertex Pharmaceuticals, Santhera Pharmaceuticals, Laurent Pharmaceuticals Inc., and others.
• Cystic Fibrosis Pipeline Therapies- Ciprofloxacin (Cipro Inhale), BAYQ3939, P-1037, Hypertonic Saline, VX-371 + HS, inhaled mannitol, and others.
• Cystic Fibrosis Market Dynamics: Cystic Fibrosis Market Drivers and Barriers
• Cystic Fibrosis Market Access and Reimbursement, Unmet Needs, and Future Perspectives

Discover more about Cystic Fibrosis Drugs in development @ Cystic Fibrosis Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/cystic-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Cystic Fibrosis Report Introduction
3. Cystic Fibrosis Market Overview at a Glance
4. Cystic Fibrosis Market: Future Perspective
5. Cystic Fibrosis Executive Summary
6. Key Events
7. Cystic Fibrosis Disease Background and Overview
8. Cystic Fibrosis Epidemiology and Patient Population
9. Patient Journey
10. Cystic Fibrosis Marketed Drugs
11. Cystic Fibrosis Emerging Drugs
12. Cystic Fibrosis: Seven Major Market Analysis
13. Key Opinion Leaders' View
14. Cystic Fibrosis Market Drivers
15. Cystic Fibrosis Market Barriers
16. Cystic Fibrosis SWOT Analysis
17. Cystic Fibrosis Unmet Needs
18. Reimbursement and Cystic Fibrosis Market Access
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com

This release was published on openPR.